Resultados da busca - Devender Dhanda

  • Mostrando 1 - 5 resultados de 5
Refinar Resultados
  1. 1
    Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma

    Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma por Michel Delforge, Nina Shah, Jesús F. San Miguel, Julia Braverman, Devender Dhanda, Ling Shi, Shien Guo, Peiwen Yu, Weiqin Liao, Timothy Campbell, Nikhil C. Munshi

    Publicado em 2021
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  2. 2
    Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial

    Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings f... por Michel Delforge, Paula Rodríguez‐Otero, Nina Shah, Olga Moshkovich, Julia Braverman, Devender Dhanda, Sally Lanar, Jennifer Devlen, Matthew Miera, Heather Gerould, Timothy Campbell, Nikhil C. Munshi

    Publicado em 2023
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  3. 3
    Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

    Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma por Surbhi Sidana, Nausheen Ahmed, Othman Salim Akhtar, Michael Heim, Ruta Brazauskas, Doris K. Hansen, Christopher Ferreri, Ciara L. Freeman, Aimaz Afrough, Larry D. Anderson, Binod Dhakal, Devender Dhanda, Lohith Gowda, Hamza Hashmi, Melanie Harrison, Amani Kitali, Abu‐Sayeef Mirza, Jinalben Patel, Pallavi Patwardhan, Saad Z. Usmani, Krina K. Patel, Siddhartha Ganguly, Marcelo C. Pasquini

    Publicado em 2023
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  4. 4
    Standard-of-Care Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis

    Standard-of-Care Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis por Surbhi Sidana, Nausheen Ahmed, Othman Salim Akhtar, Ruta Brazauskas, Temitope Oloyede, Matthew Bye, Doris K. Hansen, Christopher Ferreri, Ciara L. Freeman, Aimaz Afrough, Larry D. Anderson, Binod Dhakal, Devender Dhanda, Lohith Gowda, Hamza Hashmi, Melanie J. Harrison, Amani Kitali, Heather Landau, Abu‐Sayeef Mirza, Pallavi Patwardhan, Muzaffar H. Qazilbash, Saad Z. Usmani, Krina K. Patel, Taiga Nishihori, Siddhartha Ganguly, Marcelo C. Pasquini

    Publicado em 2025
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  5. 5
    Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

    Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses por Sikander Ailawadhi, Bertrand Arnulf, Krina K. Patel, Michèle Cavo, Ajay K. Nooka, Salomon Manier, Natalie S. Callander, Luciano J. Costa, Ravi Vij, Nizar J. Bahlis, Philippe Moreau, Scott R. Solomon, Ingerid Weum Abrahamsen, Rachid Baz, Annemiek Broijl, Christine Chen, Sundar Jagannath, Noopur Raje, Christof Scheid, Michel Delforge, Reuben Benjamin, Thomas Pabst, Shinsuke Iida, Jesús G. Berdeja, Sergio Giralt, Anna Truppel-Hartmann, Yanping Chen, Xiaobo Zhong, Fan Wu, Julia Piasecki, Laurie Eliason, Devender Dhanda, Jasper Felten, Andrea Caia, Mark Cook, Mihaela Popa-McKiver, Paula Rodríguez‐Otero

    Publicado em 2024
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:

Ferramentas de busca: